Nanovibronix (FEED) Stock Price, News & Analysis

Company Overview

Nanovibronix (NASDAQ: FEED) is a medical device company focused on the development and commercialization of non‑invasive therapeutic ultrasound technologies for clinical and consumer healthcare applications. The company's product portfolio centers on wearable ultrasound devices designed to deliver low‑intensity acoustic energy to soft tissue with the objective of promoting wound healing and reducing pain. Nanovibronix positions its technology as an alternative or adjunct to conventional wound‑care and analgesic therapies, aiming to address chronic and acute conditions that are managed in both outpatient and home settings.

The company concentrates its commercial efforts on supplying hospitals, wound‑care clinics, long‑term care facilities and patients requiring home‑based therapies. Its offerings are intended to be user‑friendly, portable and suitable for repeated application, which supports adoption in ambulatory care and self‑care environments. Nanovibronix emphasizes clinical research and device development to validate therapeutic effects and to support regulatory and reimbursement discussions in the markets it serves.

As a publicly traded entity on the NASDAQ exchange under the ticker FEED, Nanovibronix engages in the full product lifecycle from research and development through manufacturing, regulatory engagement and distribution. The company has historically sought to expand market access through clinical collaborations, distribution partnerships and targeted commercialization initiatives. Detailed, current information about specific products, regulatory clearances, market geographies or executive leadership was not available in the material used to prepare this summary.

Key Stats

• Today's Range: $0.37 to $0.48
• 50-Day Range: $0.32 to $0.88
• 52-Week Range: $0.29 to $17.40
• Volume: 857,848 shs
• Average Volume: 1.61 million shs
• Market Capitalization: $2.66 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Nanovibronix Stock Analysis - MarketRank™

Nanovibronix scored higher than 28% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Nanovibronix has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Nanovibronix has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Nanovibronix is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Nanovibronix is -0.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Nanovibronix has a P/B Ratio of 0.01. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.40% of the float of Nanovibronix has been sold short.

Short Interest Ratio / Days to Cover

Nanovibronix has a short interest ratio ("days to cover") of 0.37, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Nanovibronix has recently decreased by 53.63%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Nanovibronix does not currently pay a dividend.

Dividend Growth

Nanovibronix does not have a long track record of dividend growth.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 0.96

News Sentiment

Nanovibronix has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.67 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Nanovibronix this week, compared to 2 articles on an average week.

Search Interest

Only 3 people have searched for FEED on MarketBeat in the last 30 days. This is a decrease of -82% compared to the previous 30 days.

MarketBeat Follows

2 people have added Nanovibronix to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Nanovibronix insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $144,900.00 in company stock.

Percentage Held by Insiders

12.20% of the stock of Nanovibronix is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

16.39% of the stock of Nanovibronix is held by institutions.

Company Calendar

• Last Earnings: 5/18/2026
• Today: 8/16/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:FEED
• CIK: 1326706
• Web: nanovibronix.com
• Phone: (914) 233-3004
• Fax: 914-376-6111
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($8.82)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$18.18 million
• Net Margins: -923.20%
• Pretax Margin: -936.45%
• Return on Equity: -54.25%
• Return on Assets: -43.10%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.90
• Quick Ratio: 0.57

Sales & Book Value

• Annual Sales: $2.55 million
• Price / Sales: 1.04
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $30.44 per share
• Price / Book: 0.01

Miscellaneous

• Outstanding Shares: 6,090,000
• Free Float: 5,349,000
• Market Cap: $2.66 million
• Optionable: N/A
• Beta: 1.39